Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$4.26 +2.2%	$2.73	$1.03 ▼ $4.40	$835.41M	1.54	7.01 million shs	7.34 million shs
GYRE Gyre Therapeutics	$7.02 +5.6%	$7.88	$6.11 ▼ $19.00	$623.49M	1.8	84,052 shs	76,581 shs
SLS SELLAS Life Sciences Group	$1.59 -4.2%	$1.79	$0.77 ▼ $2.27	$165.63M	2.26	2.78 million shs	1.47 million shs
STOK Stoke Therapeutics	$13.14 +1.8%	$11.76	$5.35 ▼ $16.15	$704.85M	1.15	796,838 shs	349,880 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	+2.16%	+27.93%	+53.51%	+208.70%	+206.47%
GYRE Gyre Therapeutics	+5.56%	-10.12%	-13.76%	-19.50%	-34.94%
SLS SELLAS Life Sciences Group	-4.22%	-10.67%	-26.90%	-7.56%	+32.50%
STOK Stoke Therapeutics	+1.78%	+2.58%	+14.41%	+50.17%	-9.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.0058 of 5 stars	4.7	1.0	0.0	0.0	1.9	1.7	0.6
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	2.3364 of 5 stars	3.5	1.0	0.0	0.0	3.2	1.7	0.6
STOK Stoke Therapeutics	4.0253 of 5 stars	3.6	1.0	0.0	4.8	2.3	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.40	Buy	$11.25	164.08% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	340.25% Upside
STOK Stoke Therapeutics	3.29	Buy	$25.80	96.35% Upside

Current Analyst Ratings Breakdown

Latest SLS, GYRE, STOK, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $15.00
7/29/2025	ATAI atai Life Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
7/28/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	2,753.06	N/A	N/A	$0.69 per share	6.17
GYRE Gyre Therapeutics	$105.76M	6.22	$0.21 per share	33.67	$1.05 per share	6.69
SLS SELLAS Life Sciences Group	$1M	158.65	N/A	N/A	$0.13 per share	12.23
STOK Stoke Therapeutics	$36.56M	19.62	N/A	N/A	$4.32 per share	3.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.02	351.18	∞	N/A	7.20%	9.73%	7.66%	8/12/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	16.63	N/A	N/A	26.33%	19.08%	15.72%	8/6/2025 (Estimated)

Latest SLS, GYRE, STOK, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	N/A	N/A	N/A	$30.80 million	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/9/2025	Q1 2025	GYRE Gyre Therapeutics	$0.03	$0.03	N/A	N/A	$28.40 million	$22.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
GYRE Gyre Therapeutics	N/A	3.60	3.19
SLS SELLAS Life Sciences Group	N/A	4.64	4.64
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
GYRE Gyre Therapeutics	23.99%
SLS SELLAS Life Sciences Group	17.38%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
GYRE Gyre Therapeutics	10.00%
SLS SELLAS Life Sciences Group	1.20%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
GYRE Gyre Therapeutics	40	93.76 million	84.38 million	No Data
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

SLS, GYRE, STOK, and ATAI Headlines

Recent News About These Companies

Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday

2 hours ago | americanbankingnews.com

The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary

August 1, 2025 | msn.com

Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for

July 30, 2025 | zacks.com

Stoke Therapeutics (STOK) to Release Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.80 Consensus Target Price from Analysts

July 30, 2025 | americanbankingnews.com

28,600 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Bought by Dauntless Investment Group LLC

July 29, 2025 | marketbeat.com

Stoke Therapeutics Inc. Stock Grades | STOK | Barron's

July 28, 2025 | barrons.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Buy" by Analysts

July 25, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Shares Up 18.1% - Here's Why

July 22, 2025 | marketbeat.com

Kennondale Capital Management LLC Acquires Shares of 42,100 Stoke Therapeutics, Inc. (NASDAQ:STOK)

July 22, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.3% - Here's Why

July 21, 2025 | marketbeat.com

Jefferies Initiates Coverage of Stoke Therapeutics (STOK) with Buy Recommendation

July 19, 2025 | msn.com

Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug

July 19, 2025 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up - What's Next?

July 18, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Now Covered by Analysts at Jefferies Financial Group

July 18, 2025 | marketbeat.com

Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 15, 2025 | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago

July 15, 2025 | finance.yahoo.com

The charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'

July 13, 2025 | msn.com

New Royal Stoke technology cuts hospital stays by over a day

July 13, 2025 | msn.com

Stoke City Boss Delighted To Finally Get Signing Over The Line

July 13, 2025 | therealefl.co.ukT

Grit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winter

July 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, GYRE, STOK, and ATAI Company Descriptions

atai Life Sciences NASDAQ:ATAI

$4.26 +0.09 (+2.16%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$4.24 -0.02 (-0.47%)

As of 08/4/2025 07:55 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Gyre Therapeutics NASDAQ:GYRE

$7.02 +0.37 (+5.56%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$7.02 0.00 (-0.07%)

As of 08/4/2025 04:10 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.59 -0.07 (-4.22%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$1.60 +0.01 (+0.63%)

As of 08/4/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Stoke Therapeutics NASDAQ:STOK

$13.14 +0.23 (+1.78%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$13.22 +0.08 (+0.61%)

As of 08/4/2025 06:12 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time